Browsing by author "Huang, Paul"
Now showing items 1-20 of 72
-
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ... -
A mouse SWATH-mass spectrometry reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts.
Krasny, L; Bland, P; Burns, J; Lima, NC; Harrison, PT; et al. (COMPANY BIOLOGISTS LTD, 2020-06-03)SWATH-mass spectrometry (MS) enables accurate and reproducible proteomic profiling in multiple model organisms including the mouse. Here, we present a comprehensive mouse reference spectral library (MouseRefSWATH) that ... -
Advances in mass spectrometry based strategies to study receptor tyrosine kinases.
Vyse, S; Desmond, H; Huang, PH (INT UNION CRYSTALLOGRAPHY, 2017-02-23)Receptor tyrosine kinases (RTKs) are key transmembrane environmental sensors that are capable of transmitting extracellular information into phenotypic responses, including cell proliferation, survival and metabolism. ... -
Advances in the proteomic profiling of the matrisome and adhesome.
Krasny, L; Huang, PH (TAYLOR & FRANCIS LTD, 2021-09-02)INTRODUCTION: The matrisome and adhesome comprise proteins that are found within or are associated with the extracellular matrix (ECM) and adhesion complexes, respectively. Interactions between cells and their microenvironment ... -
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
Vyse, S; Huang, PH (TAYLOR & FRANCIS LTD, 2022-01-02)INTRODUCTION: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations ... -
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke, A; Gennatas, S; Huang, P; Jones, RL (FUTURE MEDICINE LTD, 2020-08-01)Gastrointestinal stromal tumors (GIST) can be molecularly classified based on different subtypes including mutations in KIT and PDGFRA. Patients with PDGFRA mutations are an important subgroup that commonly arise in the ... -
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma.
Kerrison, WGJ; Ning, J; Krasny, L; Arthur, A; Guljar, N; et al. (MDPI, 2022-08-04)Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines which suffer ... -
Clinical and Molecular Spectrum of Liposarcoma.
Lee, ATJ; Thway, K; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2018-01-10)Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ... -
Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.
Cojocaru, E; Palahepitiva Gamage, G; Butler, J; Barton, DP; Thway, K; et al. (ELSEVIER SCIENCE INC, 2021-03-01)Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ... -
Comparative proteomic assessment of matrisome enrichment methodologies.
Krasny, L; Paul, A; Wai, P; Howard, BA; Natrajan, RC; et al. (PORTLAND PRESS LTD, 2016-11-01)The matrisome is a complex and heterogeneous collection of extracellular matrix (ECM) and ECM-associated proteins that play important roles in tissue development and homeostasis. While several strategies for matrisome ... -
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Chrisochoidou, Y; Roy, R; Farahmand, P; Gonzalez, G; Doig, J; et al. (SPRINGERNATURE, 2023-11-08)Mesothelioma is an aggressive cancer of the mesothelial layer associated with an extensive fibrotic response. The latter is in large part mediated by cancer-associated fibroblasts which mediate tumour progression and poor ... -
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis.
Arthur, A; Orton, MR; Emsley, R; Vit, S; Kelly-Morland, C; et al. (ELSEVIER SCIENCE INC, 2023-11-01)BACKGROUND: Retroperitoneal sarcomas are tumours with a poor prognosis. Upfront characterisation of the tumour is difficult, and under-grading is common. Radiomics has the potential to non-invasively characterise the ... -
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison, WGJ; Lee, ATJ; Thway, K; Jones, RL; Huang, PH (MDPI, 2022-02-28)Immunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. ... -
Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology.
Krasny, L; Huang, PH (ROYAL SOC CHEMISTRY, 2020-10-09)Data-independent acquisition mass spectrometry (DIA-MS) is a next generation proteomic methodology that generates permanent digital proteome maps offering highly reproducible retrospective analysis of cellular and tissue ... -
Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining.
Cook, R; Zoumpoulidou, G; Luczynski, MT; Rieger, S; Moquet, J; et al. (CELL PRESS, 2015-03-31)Deficiencies in DNA double-strand break (DSB) repair lead to genetic instability, a recognized cause of cancer initiation and evolution. We report that the retinoblastoma tumor suppressor protein (RB1) is required for DNA ... -
Drug repositioning in sarcomas and other rare tumors.
Lee, ATJ; Huang, PH; Pollack, SM; Jones, RL (ELSEVIER SCIENCE BV, 2016-03-17) -
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.
Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; et al. (CELL PRESS, 2016-10-25)Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ... -
Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips, E; Jones, RL; Huang, P; Digklia, A (FRONTIERS MEDIA SA, 2022-03-30)Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated ... -
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Cojocaru, E; Thway, K; Fisher, C; Messiou, C; Zaidi, S; et al. (INT INST ANTICANCER RESEARCH, 2020-12-01)BACKGROUND/AIM: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant ... -
EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.
Pacini, L; Cabal, VN; Hermsen, MA; Huang, PH (MDPI, 2022-01-13)Recurrent epidermal growth factor receptor (EGFR)-activating mutations have been identified in a rare form of head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC), a malignant disease with a 5-year ...